G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
115 hedge funds and large institutions have $184M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 45 reducing their positions, and 11 closing their positions.
95% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $636K
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
6% more funds holding
Funds holding: 108 → 115 (+7)
32% less capital invested
Capital invested by funds: $270M → $184M (-$86.2M)
40% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.58M |
| 2 |
CA
CHI Advisors
New York
|
+$2.45M |
| 3 |
HF
HRT Financial
New York
|
+$1.94M |
| 4 |
PCM
Pinz Capital Management
New York
|
+$1.77M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.25M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.93M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.89M |
| 4 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$4.82M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.73M |
GTHX Hedge Fund Activity: Q1 2022 in Review
115 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q1 2022, worth a combined $184M — down 32% from $270M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GTHX positions and 11 closed out — a net gain of 7 holders — while 27 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.58M. The largest seller was T. Rowe Price Associates, cutting an estimated $6.25M.
- 115 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q1 2022, up from 108 in Q4 2021.
- Funds reported $184M of G1 Therapeutics, Inc. Common Stock stock for Q1 2022, down 32% quarter-over-quarter.
- 18 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q1 2022 and 11 closed out, a net change of +7 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q1 2022 was Fidelity Investments, an estimated $3.58M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q1 2022 was T. Rowe Price Associates, an estimated $6.25M sold.
Based on aggregated 13F filings for Q1 2022.